# A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients

> **NCT04629404** · PHASE1 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** LY03003
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04629404
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-05
- **Primary completion:** 2019-03-14
- **Final completion:** 2019-03-14
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629404, "A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04629404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*